Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polychlorinated Dibenzodioxins | 3 | 1999 | 12 | 0.460 |
Why?
|
| Fetus | 2 | 1999 | 77 | 0.300 |
Why?
|
| Immune System | 2 | 1997 | 29 | 0.290 |
Why?
|
| Hypersensitivity, Delayed | 2 | 1999 | 4 | 0.200 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2002 | 7 | 0.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 1997 | 96 | 0.170 |
Why?
|
| Bone Marrow | 2 | 2017 | 76 | 0.160 |
Why?
|
| Osteosarcoma | 1 | 2017 | 14 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 27 | 0.140 |
Why?
|
| Rats, Inbred F344 | 3 | 1999 | 167 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 3 | 1999 | 56 | 0.110 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2012 | 8 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2009 | 57 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 26 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2006 | 441 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2010 | 16 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2010 | 12 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 364 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 40 | 0.090 |
Why?
|
| Rats | 3 | 1999 | 1544 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 32 | 0.090 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2008 | 9 | 0.080 |
Why?
|
| Hemangioblastoma | 1 | 2008 | 12 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 251 | 0.080 |
Why?
|
| Glioma | 1 | 2009 | 118 | 0.080 |
Why?
|
| Organ Size | 2 | 1997 | 83 | 0.070 |
Why?
|
| Thymus Gland | 2 | 1997 | 53 | 0.070 |
Why?
|
| Administration, Oral | 2 | 1997 | 166 | 0.070 |
Why?
|
| Mesothelioma | 1 | 2006 | 5 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2006 | 14 | 0.070 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2006 | 6 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 31 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 288 | 0.070 |
Why?
|
| Calcium | 1 | 2006 | 231 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 441 | 0.060 |
Why?
|
| Female | 6 | 2017 | 14434 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2005 | 9 | 0.060 |
Why?
|
| Pregnancy | 2 | 1997 | 1127 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 274 | 0.050 |
Why?
|
| Animals | 4 | 2009 | 9943 | 0.050 |
Why?
|
| Humans | 9 | 2017 | 26789 | 0.050 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2002 | 2 | 0.050 |
Why?
|
| Liver | 2 | 2012 | 415 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2006 | 282 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 270 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 464 | 0.050 |
Why?
|
| Cold Temperature | 1 | 2002 | 34 | 0.050 |
Why?
|
| Cytogenetics | 2 | 2012 | 4 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2002 | 83 | 0.050 |
Why?
|
| Chromosome Aberrations | 2 | 2012 | 36 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2002 | 84 | 0.050 |
Why?
|
| Male | 5 | 2012 | 12854 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1999 | 58 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2002 | 463 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1999 | 64 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 1997 | 9 | 0.040 |
Why?
|
| Antibody Formation | 1 | 1997 | 75 | 0.040 |
Why?
|
| Spleen | 1 | 1997 | 109 | 0.040 |
Why?
|
| Methotrexate | 1 | 2017 | 32 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 1997 | 163 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2017 | 66 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2017 | 74 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 310 | 0.030 |
Why?
|
| Body Weight | 1 | 1997 | 246 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 204 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2009 | 503 | 0.030 |
Why?
|
| Cisplatin | 1 | 2017 | 172 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2009 | 766 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 801 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2006 | 1263 | 0.030 |
Why?
|
| Biopsy | 1 | 2012 | 199 | 0.020 |
Why?
|
| Karyotyping | 1 | 2010 | 24 | 0.020 |
Why?
|
| Child | 1 | 2017 | 2141 | 0.020 |
Why?
|
| Middle Aged | 2 | 2012 | 6803 | 0.020 |
Why?
|
| Topotecan | 1 | 2009 | 12 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 65 | 0.020 |
Why?
|
| Luciferases | 1 | 2009 | 49 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 367 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 100 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2009 | 92 | 0.020 |
Why?
|
| Nervous System | 1 | 2008 | 12 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 323 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 313 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 130 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 47 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 144 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 759 | 0.020 |
Why?
|
| DNA Damage | 1 | 2009 | 149 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 123 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 453 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 316 | 0.020 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2006 | 1 | 0.020 |
Why?
|
| rap1 GTP-Binding Proteins | 1 | 2006 | 1 | 0.020 |
Why?
|
| Connexin 43 | 1 | 2006 | 3 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2009 | 645 | 0.020 |
Why?
|
| Isoquinolines | 1 | 2006 | 14 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 45 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 450 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Collagenases | 1 | 2006 | 5 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2006 | 74 | 0.020 |
Why?
|
| CpG Islands | 1 | 2006 | 23 | 0.020 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2006 | 14 | 0.020 |
Why?
|
| Nitrogen | 1 | 2006 | 68 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2006 | 27 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 88 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 68 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 376 | 0.020 |
Why?
|
| Astrocytoma | 1 | 2006 | 35 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2008 | 394 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 180 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 124 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2006 | 113 | 0.020 |
Why?
|
| Apoptosis | 1 | 2009 | 739 | 0.020 |
Why?
|
| Biomarkers | 1 | 2008 | 731 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2006 | 95 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 393 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 101 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 482 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 4399 | 0.010 |
Why?
|